- Home
- AHG vs KALV Comparison
AHG vs KALV Comparison
Compare AHG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- KALV
- Stock Information
- Founded
- AHG 2013
- KALV N/A
- Country
- AHG China
- KALV United States
- Employees
- AHG N/A
- KALV N/A
- Industry
- AHG Business Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- KALV Health Care
- Exchange
- AHG Nasdaq
- KALV Nasdaq
- Market Cap
- AHG 446.7M
- KALV 362.2M
- IPO Year
- AHG N/A
- KALV N/A
- Fundamental
- Price
- AHG $1.30
- KALV $10.03
- Analyst Decision
- AHG
- KALV Strong Buy
- Analyst Count
- AHG 0
- KALV 8
- Target Price
- AHG N/A
- KALV $25.67
- AVG Volume (30 Days)
- AHG 10.8K
- KALV 321.8K
- Earning Date
- AHG 02-28-2025
- KALV 03-10-2025
- Dividend Yield
- AHG N/A
- KALV N/A
- EPS Growth
- AHG N/A
- KALV N/A
- EPS
- AHG N/A
- KALV N/A
- Revenue
- AHG $2,414,338.00
- KALV N/A
- Revenue This Year
- AHG N/A
- KALV N/A
- Revenue Next Year
- AHG N/A
- KALV N/A
- P/E Ratio
- AHG N/A
- KALV N/A
- Revenue Growth
- AHG N/A
- KALV N/A
- 52 Week Low
- AHG $0.60
- KALV $7.30
- 52 Week High
- AHG $2.35
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- AHG 50.28
- KALV 59.09
- Support Level
- AHG $1.27
- KALV $8.99
- Resistance Level
- AHG $1.45
- KALV $11.00
- Average True Range (ATR)
- AHG 0.13
- KALV 0.57
- MACD
- AHG -0.00
- KALV 0.11
- Stochastic Oscillator
- AHG 51.61
- KALV 57.08
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.